New drugs for children and adolescents with cancer: the need for novel development pathways
- 20 February 2013
- journal article
- series
- Published by Elsevier BV in The Lancet Oncology
- Vol. 14 (3), e117-e124
- https://doi.org/10.1016/s1470-2045(13)70013-5
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Dose‐finding designs using a novel quasi‐continuous endpoint for multiple toxicitiesStatistics in Medicine, 2013
- Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyThe Lancet Oncology, 2012
- Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline frameworkContemporary Clinical Trials, 2012
- Dissecting the genomic complexity underlying medulloblastomaNature, 2012
- The Pediatric Cancer Genome ProjectNature Genetics, 2012
- Genetically engineered murine models – Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastomaSeminars in Cancer Biology, 2011
- Dose‐finding approach for dose escalation with overdose control considering incomplete observationsStatistics in Medicine, 2011
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyThe Lancet Oncology, 2010
- Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conferencePediatric Blood & Cancer, 2010
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008